Company: PFSA
Filing Date: 2025-04-03
Form Type: S-4/A
Source: 0001213900-25-028544
Chunk: 47

Company: Profusa, Inc.
Filing Date: 2025-04-03
Form: S-4/A
Chunk 47
---
 Adjournment Proposal.” NorthView will hold the Special Meeting to consider and vote upon these proposals. This proxy statement/prospectus contains important information about the proposed Business Combination and the other matters to be acted upon at the Special Meeting. Stockholders should read this proxy statement/prospectus carefully, including the Annexes and the other documents referred to herein. Consummation of the Business Combination is conditional on approval of each of the Business Combination Proposal, the Charter Proposal, the Equity Incentive Plan Proposal, the ESPP Proposal, and the Nasdaq Proposals, subject to the terms of the Merger Agreement. If any of these proposals is not approved, the other proposals, except the Adjournment Proposal, will not be presented to stockholders for a vote. The vote of stockholders is important. Stockholders are encouraged to vote as soon as possible after carefully reviewing this proxy statement/prospectus. xxi Q:I am a NorthView Warrant holder. Why am I receiving this proxy statement/prospectus? A:Upon consummation of the Business Combination, the NorthView Warrants shall, by their terms, entitle the holders to purchase New Profusa Common Stock at a purchase price of $11.50 per share beginning 30 days after the consummation of the Business Combination. This proxy statement/prospectus includes important information about Profusa and the business of Profusa following consummation of the Business Combination. As holders of NorthView Warrants will be entitled to purchase New Profusa Common Stock upon consummation of the Business Combination, NorthView urges you to read the information contained in this proxy statement/prospectus carefully. Q:How has the announcement of the Business Combination affected the trading price of NorthView’s securities? The market value of the publicly traded common stock of NorthView on November 4, 2022, the last trading day preceding NorthView’s public announcement of the proposed Business Combination transaction was $9.98. The NorthView Warrants and NorthView Rights did not trade on November 4, 2022. On [ ], the most recent practicable date prior to the date of this proxy statement/prospectus, the NorthView Common Stock, NorthView Public Warrants and NorthView Rights closed at $[ ], $[] and $[], respectively. Q:What will happen to NorthView’s securities upon consummation of the Business Combination? A:NorthView Common Stock, NorthView Rights and NorthView Warrants are currently quoted on OTC Pink under the symbols NV